Lublin, Poland

Centrum Zdrowia i Urody MaxxMed

Atopic Dermatitis

Psoriasis

Eczema

Tremor

Parkinson Disease

Movement Disorders

Essential Tremor

Rocatinlimab

ABP 501

ABP 654

Humira®

CVN424

JZP385

Amgen

Cerevance

Jazz Pharmaceuticals

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Centrum Zdrowia i Urody MaxxMed | Lublin, Poland

Site insights

Work at this site?

Active trials

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Trial sponsors